子宫癌患者术后静脉血栓栓塞风险分层
这项回顾性队列研究纳入954例子宫癌子宫切除术患者,评估改良Caprini评分与Khorana评分对术后90天内静脉血栓栓塞的风险分层能力。静脉血栓栓塞发生率为1.7%(16/954),仅Caprini评分≥8或≥9有统计学意义,曲线下面积分别为0.75和0.68。作者认为改良Caprini评分有助于识别可从延长血栓预防中获益的最高危患者。
要点
- 子宫癌子宫切除术后90天内静脉血栓栓塞发生率为1.7%(16/954)。
- 仅改良Caprini评分≥8(风险比31.25)或≥9(风险比4.59)与静脉血栓栓塞有统计学关联。
- 微创手术同日出院且未接受术后血栓预防的患者(101/863)均未发生静脉血栓栓塞。
核心结论
- 作者认为使用改良Caprini评分可能有助于识别可从延长血栓预防中获益的最高危患者,可能降低术后静脉血栓栓塞发生率,并可能减少过度治疗的费用和伤害。
- 这些发现需要前瞻性验证,需要进一步研究确定最佳治疗持续时间。
研究设计与样本
- 经机构审查委员会批准后开展的回顾性队列研究,纳入4年期间所有接受子宫切除术的子宫癌患者,共954例。
- 计算每例患者的Caprini评分和Khorana评分,Caprini评分评估≥7、≥8、≥9三个截断值(改良Caprini),Khorana评分评估≥2和≥3两个截断值。
- 采用独立t检验、卡方检验或Fisher精确检验进行单因素分析,采用逻辑回归进行多因素分析。
主要发现
- 静脉血栓栓塞发生率为1.7%(16/954),90.5%(863/954)的患者采用微创手术方式。
- 静脉血栓栓塞组平均Caprini评分为10.3,无静脉血栓栓塞组为8.1(95%CI 1.17-3.33;P<.0001)。
- 静脉血栓栓塞组平均Khorana评分为2.4,无静脉血栓栓塞组为1.9(95%CI 0.04-0.82;P=.03)。
- Caprini评分≥8的风险比为31.25(95%CI 1.88-519.49),≥9的风险比为4.59(95%CI 1.49-14.13),曲线下面积分别为0.75和0.68。
- 微创手术亚组中11.7%(101/863)的患者同日出院且未接受术后血栓预防,这些患者均未发生静脉血栓栓塞;开腹手术患者尽管接受延长预防(30天),静脉血栓栓塞发生率仍超过微创组的3倍(5.49% vs 1.7%)。
关键数值与推荐
- Caprini评分≥8的风险比为31.25(95%CI 1.88-519.49),曲线下面积0.75;Caprini评分≥9的风险比为4.59(95%CI 1.49-14.13),曲线下面积0.68。
- Caprini评分≥7、Khorana评分≥2或≥3未报告有统计学意义。
临床怎么用
- 作者认为改良Caprini评分可能有助于识别可从延长血栓预防中获益的最高危患者,可能降低术后静脉血栓栓塞发生率,并可能减少过度治疗的费用和伤害。
- 作者指出这些发现需要前瞻性验证,需要进一步研究确定最佳治疗持续时间。
局限性
- 原文未报告局限性。
- 作者在结论中指出这些发现需要前瞻性验证,需要进一步研究确定最佳治疗持续时间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Uterine cancers are associated with a high risk for venous thromboembolisms. The American Society of Clinical Oncology practice guidelines recommend that all patients undergoing pelvic surgery for cancer should receive extended pharmacologic thromboprophylaxis with the duration being dependent on risk. However, risk stratification for patients with uterine cancer is not clearly defined. The Caprini score is the most widely used risk assessment model but it has been found to have limited use in the gynecologic oncology population. A modified Caprini score has been explored in other populations. The Khorana score is an additional risk assessment model that has not been studied in this context. OBJECTIVE: Our objective was to evaluate the ability of a modified Caprini model and the Khorana score to risk stratify patients with uterine cancer for postoperative venous thromboembolisms within 90 days of surgery. STUDY DESIGN: Following institutional review board approval, a retrospective cohort study was performed, and all patients with uterine cancer who underwent a hysterectomy over a 4-year period were included. The Caprini and Khorana scores were calculated for each patient. The Caprini score cutoff for highest risk was evaluated at ≥7, ≥8, and ≥9 (modified Caprini) and the Khorana score cutoff was evaluated at ≥2 and ≥3. To determine the prognostic use of each score and other clinico-pathologic criteria related to the development of a venous thromboembolism, univariate analyses were performed using independent t tests, chi-square tests, or Fisher's exact tests; a multivariate analysis was performed using logistic regression. RESULTS: A total of 954 patients were included. The rate of venous thromboembolism development was 1.7% (16/954). A minimally invasive surgical approach was used in 90.5% (863/954) of patients. The mean Caprini score for patients with a venous thromboembolism was 10.3 compared with 8.1 for patients without a venous thromboembolism (95% confidence interval, 1.17-3.33; P<.0001). The mean Khorana score for the venous thromboembolism group was 2.4 vs 1.9 for those without (95% confidence interval, 0.04-0.82; P=.03). Both the Caprini and Khorana scores were found to be associated with venous thromboembolisms, but only a Caprini score with a cutoff of ≥8 or ≥9 was statistically significant (risk ratio, 31.25; 95% confidence interval, 1.88-519.49; risk ratio, 4.59; 95% confidence interval, 1.49-14.13, respectively), with high accuracy based on the area under the curve (0.75 and 0.68, respectively). Of the minimally invasive subgroup, 11.7% (101/863) of patients had same-day discharge with no postoperative thromboprophylaxis; none of these patients developed venous thromboembolisms. Despite extended prophylaxis among the laparotomy patients (30 days), the rate of venous thromboembolisms was more than 3 times that of the minimally invasive group (5.49% vs 1.7%). Advanced tumor stage and leukocytosis were noted to be independent risk factors for venous thromboembolisms. CONCLUSION: Our study suggests that using a modified Caprini score could help to identify the highest-risk patients who would benefit from prolonged thromboprophylaxis, could reduce the incidence of postoperative venous thromboembolisms, and could minimize the cost and harm of overtreatment. These findings need to be validated in a prospective manner, and further research is needed to determine the optimal duration of therapy.
引用
- Wagner VM, Piver RN, Levine MD, et al. Postoperative venous thromboembolism risk stratification in patients with uterine cancer. Am J Obstet Gynecol. 2022. PMID: 36574873. doi:10.1016/j.ajog.2022.12.310
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。